Does Cigna Cover Prolia? A Complete Insurance Guide

What Is Prolia and Why Does Insurance Coverage Matter?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that inhibits RANK ligand (RANKL), the protein responsible for activating osteoclasts. By blocking RANKL, denosumab slows bone resorption and measurably reduces fracture risk.

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced the risk of new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo over 36 months (Cummings SR et al., NEJM 2009). Those numbers explain why prescribing physicians and patients fight hard for coverage.

The list price of a single Prolia injection sits near $1,400 as of 2024. Without insurance, two injections per year total roughly $2,800. That cost makes insurance authorization the central challenge for most patients.

How Prolia Is Administered and Why That Affects Coverage

Prolia is given as a 60 mg subcutaneous injection every 6 months, typically in a physician's office or outpatient infusion center. Because it is usually administered by a health care professional rather than self-injected at home, Cigna classifies it under the medical benefit (similar to Medicare Part B) rather than the pharmacy benefit in most plan designs.

That classification matters enormously. When Prolia falls under the medical benefit, your deductible, coinsurance, and out-of-pocket maximum for medical services apply, not your prescription drug cost-sharing tiers. Some Cigna plans have carved it into the specialty pharmacy tier instead, so always confirm which benefit category applies to your specific plan before your first injection.

FDA-Approved Indications That Cigna Recognizes

Cigna's coverage criteria align closely with FDA labeling. The agency has approved Prolia for:

• Postmenopausal women with osteoporosis at high fracture risk (T-score of -2.5 or below, or a prior fragility fracture)
• Men with osteoporosis at high fracture risk
• Men and women receiving glucocorticoid therapy (equivalent to prednisone 7.5 mg/day or more for at least 6 months) at high fracture risk
• Bone loss in men receiving androgen-deprivation therapy (ADT) for nonmetastatic prostate cancer
• Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer

Coverage for indications outside this list, such as Paget's disease or giant cell tumor (which is treated with Xgeva, a higher-dose denosumab formulation), follows a separate review path and is generally not included in routine osteoporosis coverage policies.

Does Cigna Require Prior Authorization for Prolia?

Yes. Prior authorization (PA) is required for Prolia on virtually every Cigna commercial plan, Cigna Medicare Advantage plan, and Cigna-administered ERISA self-funded plan. The PA process is not optional and cannot be bypassed by your pharmacy.

What Cigna Looks for in a Prior Authorization Request

Cigna's published coverage criteria for denosumab generally require documentation of all of the following:

1. Diagnosis confirmation. A DXA scan result showing a T-score of -2.5 or lower at the lumbar spine or hip, or documented evidence of a fragility fracture (hip, vertebral, or wrist fracture with minimal trauma), or a diagnosis of glucocorticoid-induced osteoporosis with the qualifying steroid dose and duration.

2. Prescriber specialty. The prescribing clinician must be a physician or an advanced practice provider authorized to manage metabolic bone disease. Many Cigna plans specifically list rheumatology, endocrinology, or primary care with documented osteoporosis management experience.

3. Step therapy documentation. Unless the patient has a documented contraindication or intolerance, most Cigna plans require a trial of at least one oral bisphosphonate (typically alendronate 70 mg weekly or risedronate 35 mg weekly) for a minimum of 3 to 6 months. "Failure" is defined either as a fragility fracture occurring while on bisphosphonate therapy or a documented adverse effect such as severe esophageal irritation, osteonecrosis of the jaw, or atypical femur fracture.

4. Calcium and vitamin D adequacy. Some PA checklists require documentation that the patient is receiving or has been counseled on adequate calcium (1,000 to 1,200 mg/day) and vitamin D (800 to 1,000 IU/day) supplementation, consistent with National Osteoporosis Foundation guidelines (NOF Clinician's Guide, 2022).

Step Therapy: The Biggest Barrier for New Patients

The bisphosphonate step therapy requirement is the most common reason Prolia authorizations are delayed or denied for patients who are new to osteoporosis treatment. Your prescriber should submit the PA with complete documentation of any prior bisphosphonate trial, including dates, doses, duration, and the reason for discontinuation.

If bisphosphonates are genuinely contraindicated (for example, creatinine clearance <35 mL/min makes oral bisphosphonates inappropriate per labeling), your physician should state this explicitly with supporting lab values. Cigna's reviewers are trained to approve denosumab directly when documented renal impairment precludes bisphosphonate use, because the FREEDOM trial demonstrated that denosumab efficacy is maintained across a broad range of renal function (Jamal SA et al., J Bone Miner Res 2011).

How Much Will Prolia Cost With Cigna Insurance?

After PA approval, your actual cost depends on which benefit category applies and where you are in your plan year.

Medical Benefit Cost-Sharing

When Prolia is billed under the medical benefit (CPT code 96372 for the injection plus J0897 for the drug itself), typical Cigna cost-sharing looks like this:

• Before deductible is met: You may owe the full negotiated rate for the drug (often $800 to $1,100 after Cigna's contracted discount) plus a facility fee.
• After deductible, before out-of-pocket maximum: You owe your plan's coinsurance percentage, typically 20% of the negotiated rate for in-network services.
• After out-of-pocket maximum: $0 for the remainder of the plan year.

The specific numbers vary by whether you have a PPO, HMO, EPO, or high-deductible health plan (HDHP). Call the member services number on the back of your Cigna card and ask specifically: "Is Prolia billed under my medical benefit or pharmacy benefit, and what is my coinsurance for specialty drugs administered in a physician's office?"

Specialty Pharmacy Cost-Sharing

Some Cigna plans route Prolia through a specialty pharmacy, in which case it lands on the specialty drug tier. Specialty-tier cost-sharing on Cigna commercial plans ranges from a flat $100 to $200 copay per fill to 25% to 40% coinsurance with no cap per prescription, which can mean hundreds of dollars per injection.

Manufacturer Copay Assistance

Amgen, the manufacturer of Prolia, offers the Prolia Copay Card program. Eligible commercially insured patients (those not using Medicare, Medicaid, or other federal/state programs) may pay as little as $0 per injection, with a maximum savings of $3,600 per year. Enrollment is at amgen.com and takes roughly 5 minutes online. This card cannot be used by Medicare Advantage members, which is a hard federal restriction, not a Cigna policy.

What Happens If Cigna Denies Prolia Coverage?

A denial is not the end of the road. Federal law (the ACA and ERISA) gives every insured patient the right to an internal appeal and, for fully-insured plans, an external independent review.

Step 1: Understand the Denial Reason

Cigna sends a written Explanation of Benefits (EOB) or denial notice that cites the specific reason. Common denial codes include:

• Not medically necessary (PA criteria not met, usually missing DXA data or step therapy documentation)
• Step therapy not satisfied (bisphosphonate trial not documented)
• Out-of-network provider (the infusing physician or facility is not in Cigna's network)
• Benefit exclusion (rare, usually in stripped-down plan designs)

Read the specific reason code before filing an appeal. An appeal that addresses the wrong issue will fail.

Step 2: File an Internal Appeal

You or your prescriber can file an internal appeal within the timeframe listed on the denial letter, typically 180 days for commercial plans. Your physician's office should submit:

• A detailed letter of medical necessity from the prescribing physician
• DXA scan results with the radiologist's report
• Complete medication history documenting the bisphosphonate trial or contraindication
• Relevant lab values (serum creatinine, eGFR if renal impairment is the contraindication)
• References to FREEDOM trial data and current guidelines (American Association of Clinical Endocrinologists/American College of Endocrinology 2020 Guidelines, Endocr Pract 2020)

The AACE 2020 Clinical Practice Guidelines state: "Denosumab is recommended as first-line therapy for patients at very high or imminent fracture risk and for patients with chronic kidney disease in whom bisphosphonates are contraindicated." That direct guideline language is one of the most useful passages to include in an appeal letter.

Step 3: Request a Peer-to-Peer Review

Before the internal appeal decision is issued, your physician can request a peer-to-peer call with Cigna's medical reviewer. In many cases, a 10-minute call in which the treating physician explains the clinical rationale resolves the denial without a formal appeal. Ask the PA department for the peer-to-peer request phone number; Cigna typically provides one on the denial letter.

Step 4: External Independent Review

If the internal appeal is denied, commercially insured patients in most states can request an external independent review organization (IRO) review. The IRO is not affiliated with Cigna. Studies of external reviews across all payers show that patients win approximately 40% to 45% of external IRO reviews when the denial involves a medical necessity dispute (Kaiser Family Foundation, 2023 data). The external review decision is binding on Cigna for fully-insured plans.

Cigna Medicare Advantage and Prolia

Cigna Medicare Advantage plans follow CMS coverage determinations for denosumab. Under Medicare Part B, Prolia is covered when administered in a physician's office or outpatient hospital setting for any FDA-approved indication (CMS Medicare Benefit Policy Manual, Chapter 15).

Part B vs. Part D for Cigna MA Members

Because Prolia is typically physician-administered, it falls under Part B, not Part D. The standard Medicare Part B cost-share is 20% after the Part B deductible ($240 in 2024). Cigna Medicare Advantage plans may reduce this to $0 or a fixed copay, or may increase it slightly depending on the plan's supplemental benefit design.

MA members should check their plan's Evidence of Coverage (EOC) document, specifically the "Part B drugs" section, to find the exact cost-share for CPT J0897.

Prior Authorization in Cigna Medicare Advantage

CMS permits Medicare Advantage plans to require prior authorization even for Part B-covered drugs. Cigna MA plans do require PA for Prolia. The criteria mirror commercial coverage but cannot be more restrictive than Medicare's coverage determination without documented clinical justification. If your MA plan denies Prolia for an FDA-approved indication that Medicare covers, the plan is required to re-evaluate the denial under the MA coverage rules, and you have the right to a Coverage Determination and subsequent Redetermination request.

Comparing Prolia to Other Cigna-Covered Osteoporosis Drugs

Understanding how Prolia's tier placement compares to alternatives helps in planning treatment and cost discussions with your physician.

The table below summarizes how Cigna typically classifies the major osteoporosis agents. Coverage tier and step therapy requirements vary by plan year and individual plan design, so confirm current status with Cigna member services.

| Drug | Generic available | Typical Cigna tier | PA required | Common step therapy position | |---|---|---|---|---| | Alendronate (Fosamax) | Yes | Tier 1 or 2 | No | First-line | | Risedronate (Actonel) | Yes | Tier 1 or 2 | No | First-line | | Ibandronate (Boniva) oral | Yes | Tier 2 | No | First-line option | | Zoledronic acid (Reclast) IV | Yes | Medical benefit | Often yes | Second-line | | Denosumab (Prolia) | No (biosimilars pending US approval) | Specialty or medical benefit | Yes | Second or third-line | | Teriparatide (Forteo) | No | Specialty Tier 4 | Yes | High fracture risk only | | Romosozumab (Evenity) | No | Specialty Tier 4 | Yes | Very high fracture risk | | Raloxifene (Evista) | Yes | Tier 2 | No | Alternative first-line |

Oral bisphosphonates are generic, cheap, and require no PA, which is why Cigna places them first in most step therapy protocols. Prolia's position as second or third-line in low-to-moderate risk patients is consistent with cost-management strategy, though the AACE guidelines do list it as first-line for very high fracture risk.

One nuance worth discussing with your physician: denosumab must not be discontinued abruptly. The FREEDOM Extension data showed that stopping denosumab without transitioning to a bisphosphonate can produce a rapid rebound increase in bone resorption markers and multiple vertebral fractures within 12 to 18 months (Cummings SR et al., Osteoporos Int 2018). If there is any concern about sustained insurance coverage, your physician should plan an exit strategy before starting therapy.

Practical Steps to Get Cigna to Approve Prolia

Getting approval is primarily a documentation exercise. These steps, taken in order, give your PA the best chance of approval on the first submission.

Before Submitting the PA

• Confirm your plan's current PA criteria by calling Cigna provider services at the number on your insurance card, or have your physician's office pull the current coverage policy through Cigna's provider portal.
• Get a current DXA scan with a full report. A scan older than 2 years may not satisfy the PA criteria.
• Document any prior bisphosphonate use in detail: drug name, dose, start date, stop date, and reason for stopping.
• If you have never tried a bisphosphonate and have no contraindication, discuss with your physician whether a brief documented bisphosphonate trial is feasible or whether your fracture risk is high enough to justify a direct denosumab request.

During the PA Process

• Ask the prescriber's office to submit the PA as "urgent" if you have had a recent fragility fracture. An expedited PA decision is required within 72 hours for urgent requests.
• Follow up every 3 to 5 business days. Cigna has up to 15 business days to respond to a standard PA request, but delays are common.

After PA Approval

• Confirm the approval covers the full 12-month treatment period (two injections). Some approvals are for a single injection and require re-authorization.
• Note the authorization number and expiration date. Schedule both injections (roughly 6 months apart) before the authorization expires.
• Enroll in Amgen's copay card program before the first injection if you are commercially insured and not on a federal benefit program.

The Endocrine Society's 2019 Clinical Practice Guideline on pharmacological management of osteoporosis in postmenopausal women states: "We recommend using pharmacological therapy in postmenopausal women with osteoporosis at high fracture risk, defined as a history of fragility fractures of hip or spine, T-score of -2.5 or below, or an absolute fracture risk that exceeds a country-specific threshold." (Eastell R et al., J Clin Endocrinol Metab 2019). Quoting that language directly in a PA or appeal letter grounds the request in peer-reviewed guideline evidence rather than individual physician opinion alone.

Biosimilars and the Future of Prolia Coverage

The FDA approved the first denosumab biosimilar, Jubbonti (denosumab-bbdz, Sandoz), in March 2024, followed by Wyost for the oncology indication. Cigna has not yet mandated biosimilar substitution for Prolia as of early 2025, but formulary substitution policies typically follow 6 to 18 months after biosimilar launch. When substitution begins, the biosimilar will likely occupy a lower specialty tier with reduced cost-sharing, which could substantially benefit patients currently paying high coinsurance for brand Prolia. Ask your plan administrator in mid-2025 and beyond whether denosumab biosimilars have been added to the Cigna formulary at a preferred tier.